All In Biotech

Drug Trial Radar · NCT04467905

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients With Atrial Fibrillation.

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

69

Actual

Start

Nov 19, 2020

Primary completion

Aug 3, 2023

Study completion Aug 10, 2023

Sponsor

Lead sponsor
Milestone Pharmaceuticals Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Montreal Health Innovations Coordinating Center (MHICC); JSS Medical Research Inc.
First posted
Jul 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Many patients with atrial fibrillation (AF) experience persistent tachycardia with episodes of rapid ventricular rate despite chronic treatment to reduce ventricular rate. The objectives of this study were to demonstrate the superiority of a nasal spray of etripamil over placebo in reducing ventricular rate in patients with AF; and to evaluate the safety and efficacy of etripamil nasal spray in participants with AF.

Conditions

  • Atrial Fibrillation

Interventions

  • EtripamilDrug

    The formulation of etripamil nasal spray consists of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.

  • PlaceboDrug

    The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration.Time frame: 60 minutes post drug administration

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • QEII HSC - Nova Scotia Health Authority

    Halifax, Nova Scotia, Canada

  • Hamilton Health Science

    Hamilton, Ontario, Canada

  • PACE (Partners in Advanced Cardiac Evaluation)

    Newmarket, Ontario, Canada

  • Ottawa Hospital General & Civic Campus Research Institute

    Ottawa, Ontario, Canada

  • Institut de Cardiologie de Montreal

    Montreal, Quebec, Canada

  • CHU Montréal

    Montreal, Quebec, Canada

  • CIUSSS du Nord-de-l'Île-de-Montréal - Hôpital du Sacré-Cœur

    Montreal, Quebec, Canada

  • CISSS Bas-Saint-Laurent / Hôpital de Rimouski

    Rimouski, Quebec, Canada

  • CISSS des Laurentides / Unité de recherche clinique

    Saint-Jérôme, Quebec, Canada

  • CIUSSS de l'Estrie - CHU

    Sherbrooke, Quebec, Canada

  • CISSS de Lanaudière - Hôpital Pierre-Le Gardeur

    Terrebonne, Quebec, Canada

  • Jeroen Bosch Ziekenhuis

    's-Hertogenbosch, Netherlands

  • Jeroen Bosch Ziekenhuis Rijnstate Ziekenhuis

    Arnhem, Netherlands

  • Slingeland Ziekenhuis

    Doetinchem, Netherlands

  • Treant Zorggroep

    Emmen, Netherlands

  • Elkerliek Ziekenhuis

    Helmond, Netherlands

  • Franciscus Gasthuis

    Rotterdam, Netherlands

  • Gelre Ziekenhuizen

    Zutphen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.